| Dermatitis
Adbry vs Texacort
Side-by-side clinical, coverage, and cost comparison for dermatitis.Deep comparison between: Adbry vs Texacort with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTexacort has a higher rate of injection site reactions vs Adbry based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Texacort but not Adbry, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Adbry
Texacort
At A Glance
SC injection
Every 2-4 weeks
IL-13 antagonist
Topical
3-4 times daily
Corticosteroid
Indications
- Dermatitis
- Dermatitis
Dosing
Dermatitis - Adults 600 mg SC loading dose (four 150 mg prefilled syringes or two 300 mg autoinjectors), then 300 mg SC every other week; after 16 weeks, adults below 100 kg who achieve clear or almost clear skin may reduce to 300 mg every 4 weeks.
Dermatitis - Pediatric Patients 12 Years and Older 300 mg SC loading dose (two 150 mg prefilled syringes), then 150 mg SC every other week using prefilled syringe.
Dermatitis Apply a thin film to the affected area three or four times daily depending on severity; occlusive dressings may be used for psoriasis or recalcitrant conditions.
Contraindications
- Known hypersensitivity to tralokinumab-ldrm or any excipients in ADBRY
- History of hypersensitivity to any component of the preparation
Adverse Reactions
Most common (>=1%) Upper respiratory tract infections, conjunctivitis, injection site reactions, eosinophilia
Conjunctivitis and Keratitis Conjunctivitis (including allergic conjunctivitis), keratoconjunctivitis, keratitis (including ulcerative keratitis)
Most common burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria
Pharmacology
IL-13 antagonist; tralokinumab-ldrm is a human IgG4 monoclonal antibody that specifically binds to IL-13 and blocks its interaction with IL-13Ralpha1 and IL-13Ralpha2 receptor subunits, inhibiting IL-13-induced proinflammatory cytokine, chemokine, and IgE release.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions; mechanisms of anti-inflammatory activity are unclear but vasoconstrictor potency may correlate with therapeutic efficacy.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Adbry
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Texacort
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Adbry
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Texacort
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Adbry
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Texacort
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAdbry Bridge Care Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Texacort.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TexacortView full Texacort profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.